CYTK — CYTOKINETICS INC

Ownership history in GSK plc  ·  1 quarter on record

This page tracks every 13F SEC filing in which GSK plc reported a position in CYTOKINETICS INC (CYTK). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
2.71% (2025 Q4)
Avg. % of fund
2.71%
First filed
2025 Q4
Last filed
2025 Q4
Quarters held
1
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 INITIATED 340,434 — — 2.71% $21.6M $63.54
% of Fund (quarterly)    CYTK price (monthly, adj. close)

Other funds also holding CYTK

As of 2025 Q4 — sorted by position size

Foresite Capital Management IV, LLC 3Y 7Y 12.68% Sarissa Capital Management LP 3Y 7Y 11.3% DAFNA Capital Management LLC 3Y 7Y 5.48% Integral Health Asset Management, LLC 3Y 4.42% Rosalind Advisors, Inc. 4.36% Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. 4.22% Melqart Asset Management (UK) Ltd 3Y 7Y 3.9% Exome Asset Management LLC 3.79% Deep Track Capital, LP 3Y 3.78% Checkpoint Capital L.P. 3.31%
← Back to GSK plc Holdings